证券之星消息，截至2026年1月30日收盘，英科医疗(300677)报收于41.86元，上涨2.57%，换手率 2.51%，成交量11.71万手，成交额4.81亿元。 1月30日的资金流向数据方面，主力资金净流入1347.49万元，占总成交额2.8%，游资资金净流入 2536.19万元，占总成交额5.27%，散户资金净流出3883.69万元，占总成交额8.07%。 | 指标 | 英科医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 274.25亿元 | 111.02亿元 | 7 127 | | 净资产 | 184.67亿元 | 38.45亿元 | 4 127 | | 净利润 | 9.24亿元 | 2.1亿元 | 7 127 | | 市盈率(动) | 22.25 | 104.17 | 16 127 | | 市净率 | 1.51 | 4.04 | 18 127 | | 毛利率 | 23.7% | 50.94% | 117 127 | | 净利率 | 12.82% | 9.66% | 54 127 | | ROE | 5.19% | 0.43% | 5 ...

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products including rehabilitation therapy, training, care, assistive devices, assessment, traditional Chinese medicine treatment, health maintenance, medical beauty, and home rehabilitation [2] - As of March 31, 2025, the company had 5,895 shareholders, an increase of 559 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's stock closed at 61.8 yuan on August 25, with a rolling price-to-earnings (PE) ratio of 113.89, significantly higher than the industry average PE of 56.14 [1][3] Group 2 - In the latest quarterly report for Q1 2025, the company achieved a revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a year-on-year decrease of 41.26% [3] - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology projects from the Chinese Rehabilitation Medicine Association and other organizations, highlighting its innovation and contribution to the field [2]

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products across 10 categories and over 1,000 types [2] - The company achieved a revenue of 186 million yuan in Q1 2025, representing a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan [3] - The company's rolling price-to-earnings (PE) ratio reached 122.02, marking a new low in 965 days, with a total market capitalization of 10.594 billion yuan [1] Group 2 - The average PE ratio for the medical device industry is 57.48, with a median of 40.95, placing the company at 107th in industry rankings [1] - The company has received multiple awards for its projects, including first prizes from the Chinese Rehabilitation Medicine Association and various provincial awards for technological advancements in rehabilitation [2] - As of March 31, 2025, the number of shareholders increased to 5,895, with an average holding value of 352,800 yuan per shareholder [1]

Company Overview - Xiangyu Medical focuses on the research, production, and sales of rehabilitation medical devices, offering a wide range of products across 10 categories and over 1,000 items [2] - The company has received multiple awards for its projects, including first prizes from the Chinese Rehabilitation Medicine Association and various provincial awards for technological advancements in rehabilitation [2] Financial Performance - For Q1 2025, the company reported a revenue of 186 million yuan, representing a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, showing a decline of 41.26% [3] - The gross profit margin stood at 65.30% [3] Market Position - As of May 29, the company's stock closed at 37.5 yuan, with a rolling price-to-earnings (PE) ratio of 69.11, significantly higher than the industry average of 49.64 and the median of 36.36 [1][3] - The total market capitalization of Xiangyu Medical is 6 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 16 institutions held shares in Xiangyu Medical, including 10 funds, with a total holding of approximately 111.63 million shares valued at 406.3 million yuan [1]